Latest Information

20.11.08 - Latest NAV performance

13.11.08 - Investment Bulletin

12.11.08 - Latest Fund Factsheets

07.11.08 - Pick of the Week

05.11.08 - 'Old Europe'

 

Fund Prices (20 Nov 2008)

A Share

£  88.41

£130.57

£132.16

£  81.01

£101.77

£  64.08

B Share

£  86.36

£128.05

£130.84

£  76.25

£101.03

£108.86

Funds under Management - £176.7 million

Unlike most fund management companies, Bedlam is structured to make investors money

Bedlam is structured to make investors money

      Pick of the Week

Bedlam is structured to make investors money Articles    
Bedlam is structured to make investors money Financials

Japan Stock Writeups

 

In contrast to our other three Japanese regional bank holdings, Eighteenth Bank produced not only disappointing results but also continuing weak guidance for the year ahead. This comes after the bank had signalled that they expect to see loans growth improve and profitability rebound. Last year they placed through a higher provisioning charge on the back of a tighter provisioning policy, hence we would have anticipated that profitability should in fact improve in the year ahead.

Eighteenth Bank. This medium-sized bank is regarded as having strong management and is ahead of the game when it comes to computerised banking. Given its market capitalisation of a little over £500m it would appear a strong candidate for consolidation. In addition first half results have surprised on the upside due to falling non-performing loans and rising revenue. Valuations look compelling.

Sedol Type Price Date
6307169 Sell JPY 509.398 16/05/2007
6307169 Buy JPY 717.824 29/03/2006
6307169 Buy JPY 709.208 28/02/2006
6307169 Buy JPY 733.656 12/12/2005
6307169 Buy JPY 786.944 02/12/2005
6307169 Buy JPY 668.75 14/11/2005
6307169 Buy JPY 598.40 24/10/2005
6307169 Buy JPY 585.853 19/10/2005

 

Eisai. This pharmaceutical company has a long track record of profitable investment generating a strong return on equity and growing earnings per share. Its share price took a tumble recently following the announcement of its acquisition of MGI Pharma, a US biotech firm with a strong pipeline of anti-cancer drugs. The market appears to have reacted to concerns about the impact on earnings of goodwill amortisation. We do not believe this non-cash amortisation is of any relevance when valuing Eisai, thus the fall in its share price offered an attractive entry point.

Sedol Type Price Date
6307200 Buy JPY 3388.139 28/03/2008

Back to Japan Stock Writeups categories View Latest Transactions

back to japan portfolio

 

View Stocks A - Z

Home
About Bedlam
Investors
Funds
Segregated Accounts
News
Archive
Financials
Contact Bedlam
www.intergage.co.uk